endocrinology
C-Peptide to Glucose Ratio
Fasting C-peptide to fasting glucose ratio helps distinguish type 1 from type 2 diabetes and assesses residual beta-cell function. Low ratio suggests type 1 or insulin deficiency; high ratio suggests type 2 or insulin resistance.
References
- Hattersley AT, Patel KA. Precision diabetes: learning from monogenic diabetes. Diabetologia. 2017;60(5):769–777.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Tirzepatide · Dual GIP/GLP-1 Receptor Agonist — Type 2 Diabetes / Obesity
- Noradrenaline (Norepinephrine) · Vasopressor (Alpha-1 and Beta-1 Agonist)
- Dobutamine (ICU — Inotrope) · Inotrope (Beta-1 Agonist)
- Insulin (IV Infusion — ICU Glucose Control) · Insulin — ICU Glucose Management
- Labetalol (IV — Hypertensive Emergency) · Combined Alpha-1 and Beta-Adrenergic Blocker
- Ephedrine hydrochloride · Mixed alpha/beta-adrenergic agonist (vasopressor)
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016
- Pituitary Apoplexy · ENEA 2011 / Pituitary Society
- Hypercalcaemia Management · NICE / Endocrine Society
Decision support only — verify against MDCalc, NICE, or your local guideline before clinical use.